外源基因经静脉途径跨血脑屏障在大鼠脑内的特异性表达
외원기인경정맥도경과혈뇌병장재대서뇌내적특이성표체
Specific expression in brain of exogenous gene by transpassing blood-brain barrier after intravenous injection
  • 万方数据
    中华医学杂志 중화의학잡지
    National Medical Journal of China
    2009年 46期 3271-3275 ,共5页

    赵浩%赵英杰%李桂林%王任直%孔燕国%冯铭%魏俊吉%栗世芳%马文斌%杨义%李永宁

    조호%조영걸%리계림%왕임직%공연국%풍명%위준길%률세방%마문빈%양의%리영저

    脂质体%神经胶质原纤维酸性蛋白质%血脑屏障%半乳糖苷酶类%转铁蛋白受体抗体 脂質體%神經膠質原纖維痠性蛋白質%血腦屏障%半乳糖苷酶類%轉鐵蛋白受體抗體
    지질체%신경효질원섬유산성단백질%혈뇌병장%반유당감매류%전철단백수체항체
    Liposomes%Glial fibrillary acidic protein%Blood-brain barrier%Galactosidases%Anti-transferrin receptor
    目的 构建脑特异性启动子GFAP启动的由转铁蛋白受体抗体(OX26)靶向的免疫脂质体0X26-pGFAP-IL,研究其携带外源基因LaeZ在大鼠脑内的表达情况.方法 将pCMV-LacZ脂质体(pCMV-Liposome)、OX26-pCMV-LacZ免疫脂质体(0X26-pCMV-IL)、0X26-pGFAP-LacZ免疫脂质体(OX26-pGFAP-IL)和空白脂质体,分别通过股静脉注射至大鼠体内.24 h后Q-PCR检测LacZ基因mRNA在脑及周围器官的表达相对量,48 h后检测LacZ基因在脑及周围器官的蛋白表达情况.结果 药物注射24 h后OX26-pCMV-IL组和OX26-pGFAP-IL组脑中LacZ基因mRNA表达相对量分别为49.2 x 10~(-6)和44.9×10~(-6),显著高于pCMV-Liposome组和空白脂质体组(P<0.05).OX26-pCMV-IL组在周围脏器的LacZ基因mRNA相对量显著高于OX26-pGFAP-IL组(P<0.05).48 h后OX26-pCMV-IL组和OX26-pGFAP-IL组脑中β-半乳糖苷酶活性分别为0.67 pg/mg和0.92 pg/mg,显著高于pCMV-Liposome组和空白脂质体组(P<0.05).OX26-pCMV-IL组和OX26-pGFAP-IL组在脑中β-半乳糖苷酶活性差异无统计学意义.组织化学染色OX26-pGFAP-IL组可以实现在脑内的特异性阳性表达,减少在周围脏器的阳性表达.结论 OX26-pGFAP-IL通过静脉途径注射后可以透过血脑屏障,在GFAP启动子的作用下实现外源基因脑内特异性的表达,同时减少在周围脏器的非特异表达,是实现颅内疾病的非病毒载体基因治疗的一种可行的方法.
    목적 구건뇌특이성계동자GFAP계동적유전철단백수체항체(OX26)파향적면역지질체0X26-pGFAP-IL,연구기휴대외원기인LaeZ재대서뇌내적표체정황.방법 장pCMV-LacZ지질체(pCMV-Liposome)、OX26-pCMV-LacZ면역지질체(0X26-pCMV-IL)、0X26-pGFAP-LacZ면역지질체(OX26-pGFAP-IL)화공백지질체,분별통과고정맥주사지대서체내.24 h후Q-PCR검측LacZ기인mRNA재뇌급주위기관적표체상대량,48 h후검측LacZ기인재뇌급주위기관적단백표체정황.결과 약물주사24 h후OX26-pCMV-IL조화OX26-pGFAP-IL조뇌중LacZ기인mRNA표체상대량분별위49.2 x 10~(-6)화44.9×10~(-6),현저고우pCMV-Liposome조화공백지질체조(P<0.05).OX26-pCMV-IL조재주위장기적LacZ기인mRNA상대량현저고우OX26-pGFAP-IL조(P<0.05).48 h후OX26-pCMV-IL조화OX26-pGFAP-IL조뇌중β-반유당감매활성분별위0.67 pg/mg화0.92 pg/mg,현저고우pCMV-Liposome조화공백지질체조(P<0.05).OX26-pCMV-IL조화OX26-pGFAP-IL조재뇌중β-반유당감매활성차이무통계학의의.조직화학염색OX26-pGFAP-IL조가이실현재뇌내적특이성양성표체,감소재주위장기적양성표체.결론 OX26-pGFAP-IL통과정맥도경주사후가이투과혈뇌병장,재GFAP계동자적작용하실현외원기인뇌내특이성적표체,동시감소재주위장기적비특이표체,시실현로내질병적비병독재체기인치료적일충가행적방법.
    Objective To study the expression of exogenous LacZ gene in brain via a delivery of OX26-pGFAP-IL.Methods pCMV-Liposome,OX26-pCMV-IL,OX26-pGFAP-IL and blank liposome were injected into rats via femoral vein.At 24 h post-injection,the method of Q-PCR was adopted to calculate the relative quantities of LaeZ gene mRNA in brain and peripheral organs.At 48 h post-injection, the protein expression of LacZ gene waS detected by the activity of β-galactosidase and the method of histochemical stain.Results The result of Q-PCR showed that,at 24 h post-injection,the relative quantities of LacZ mRNA in OX26-pCMV-IL group (49.2×10~(-6)) and OX26-pGFAP-IL group (44.9×10~(-6)) were significantly hisher than pCMV-liposome and blank liposome groups (P<0.05).In peripheral organs,the relative quantity of LacZ mRNA in OX26-pCMV-IL group were significantly higher than that in OX26-pGFAP-IL group(P<0.05).At 48 h post-injection,the activity of β-galactosidase in OX26-pCMV-Ⅱ.(0.67 pg/mg) and OX26-pGFAP-IL groups (0.92 pg/mg) were significantly higher than pCMV-liposome and blank liposome groups (P<0.05).There was no significant difference between OX26-pCMV-IL group and OX26-pGFAP-IL group in terms of the expression of β-galactosidase.The result of histochemical stain showed that OX26-pGFAP-IL achieved a specifically positive expression in brain and had a decreased expression in peripheral organs.Conclusion OX26-pGFAP-IL injected via femoral vein can cross the brain-blood barrier and achieve a specific expression in brain under the control of GFAP promoter.OX26-pGFAP-Ⅱ,decreases the non-specific expression in peripheral organs and it may be used as an non-viral gene therapy for intra-cranial diseases.
    원문보기 원문다운로드 사이트로이동
저자의 최근 논문